Dostarlimab Plus Chemo Granted EU Approval for dMMR/MSI-H En

The European Commission has granted marketing authorization to dostarlimab paired with carboplatin and paclitaxel in adults with dMMR/MSI-H primary advanced or recurrent endometrial cancer who are eligible to receive systemic treatment.

Related Keywords

, European Commission , European Union , Glaxosmithkline , European Commission , Dostarlimab , Dostarlimab Plus Carboplatin And Paclitaxel , Endometrial Cancer , Dmmr , Msi High ,